Decoding the silent walk of COVID-19: Halting its spread using old bullets
Fecha
2020Autor
Kumar, Mukesh
Madan, Jitender
Sodhi, Rupinder Kaur
Singh, Shashi Bala
Katyal, Anju
Resumen
Severe acute respiratory syndrome (SARS) develops within 3-14 days when CoV2 invades
epithelial, myeloid cells in the nasopharynx and pneumocytes in the respiratory tract through
angiotensin converting enzyme (ACE2). Infection swiftly disseminates to gastrointestinal,
cardiovascular, renal organs as well as immune system to deregulate their normal functioning
through unique and distinct mechanisms. The health system and economy has been intensely
thwarted by the rapid spread and exorbitant mortality caused by COVID-19 disease across
the globe. The acute progression of the disease and high infection rate pose an enormous
challenge for its therapeutic management and critical care. The viral structure, genome and
proteome have been deciphered which yielded cues for targeting already available therapeutic
entities. More than 200 compounds have been screened and till date approximately 69
therapeutic agents are undergoing clinical trials across the world. Among these, remedesivir
(RMD), chloroquine (CQ), hydroxychloroquine (HCQ), noscapine (NOS) and heparin have
demonstrated fairly promising results in preclinical and clinical studies. Recently, RMD has
been approved by USFDA for the management of COVID 19. However, intense research is
going on to screen and ace the ‘magic bullets’ for the management of SARS-CoV2 infection
worldwide. The current review illustrates the plausible therapeutic targets in SARS-CoV2
important for inhibition of virus cycle. In addition, the role of RMD, CQ, HCQ, NOS and
heparin in combating infection has been addressed. The importance of vitamin C and D
supplements as adjunct therapies in the prevention of SARS-CoV2 virus infection have also
been summarized.
Palabras clave
Severe acute respiratory syndrome (SARS-CoV2); Remedesivir; Chloroquine; Noscapine; Heparin; Vitamin CEnlace al recurso
https://doi.org/10.1016/j.biopha.2020.110891Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.